Journey Medical Business Summary

Journey Medical Corp (DERM) operates as a commercial-stage specialty pharmaceutical company focused on the development and commercialization of prescription treatments for dermatological conditions. The company generates revenue primarily through net product sales in the U.S. market, utilizing an efficient sales force to target high-prescribing dermatologists. Its business is bifurcated into two primary segments: a legacy portfolio of established brands such as Accutane, Amzeeq, and Zilxi, and a high-growth segment anchored by Qbrexza and the 2025 launch of Emrosi (minocycline hydrochloride), a potential best-in-class treatment for rosacea. Journey Medical competes directly with industry giants like Galderma (Oracea), Arcutis Biotherapeutics, and Sol-Gel Technologies, positioning itself as a high-margin, patent-protected alternative that leverages superior clinical efficacy data to capture market share from genericized standards of care. Founded in 2014 by Fortress Biotech and industry veteran Claude Maraoui, the leadership team is characterized by a deep pedigree in the dermatology sector, with many executives originating from Medicis Pharmaceutical Corporation. Claude Maraoui serves as President and CEO, bringing over 30 years of experience and a track record of over 50 product launches. He is supported by Joseph Benesch (CFO), who has 25 years of pharmaceutical finance experience, and Ramsey Alloush, who was promoted to Chief Operating Officer and General Counsel in 2025. The company is governed by a high-profile board led by Executive Chairman Dr. Lindsay A. Rosenwald (CEO of Fortress Biotech) and includes Justin Smith, co-founder of Skinbetter Science. Major institutional backing is provided by Fortress Biotech, which remains the largest shareholder, alongside notable investors such as Tang Capital Management and Wasatch Advisors.